Is outsourcing the most viable pathway for innovators?
There is an ever-growing market for oral solid dose development and the complex nature of new molecules has impacted outsourcing solid dose manufacturing in a number of ways.
Partnerships with contract development and manufacturing organizations (CDMOs) are crucial, as they can bring formulation expertise, global experience, and broad service offerings.
Now, innovators are choosing to share the burden of challenges relating to bioavailability, formulation, stability, manufacturability, and scalability. There are also industry pressures to reduce development times and costs, as well as increase the numbers of smaller drug developers taking molecules to market independently.
Partnerships with contract development and manufacturing organizations (CDMOs) are crucial, as they can bring formulation expertise, global experience, and broad service offerings. When selecting a CDMO, customers should look for a clean compliance record, a good supply service and a strong reputation for on-time delivery, as well as value for money through an attractive total cost of supply.
In an article with Contract Pharma, our VP of Manufacturing Services and Head of Sustainability, Erik Haeffler, discusses the manufacturing of solid dosage forms and how pharmaceutical outsourcing may be key in bringing increased flexibility and capacity to the manufacture of these drug forms.
You can read the full article by clicking here.